Enliven Therapeutics (ELVN) Research & Development (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Research & Development data on file, last reported at $20.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 16.9% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2026 stood at $81.6 million (down 4.73% YoY), and the FY2025 full-year result was $85.9 million, up 6.29% from the prior year.
• Research & Development retreated to $20.7 million in Q1 2026, from $21.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $24.9 million in Q1 2025 to a low of $7.1 million in Q1 2022.
• A 5-year average of $16.6 million and a median of $18.8 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development fell 24.7% in 2022 and surged 150.43% in 2023, its largest moves.
• Tracing ELVN's Research & Development over 5 years: stood at $8.2 million in 2022, then surged by 118.43% to $17.9 million in 2023, then rose by 15.74% to $20.7 million in 2024, then increased by 2.51% to $21.2 million in 2025, then declined by 2.63% to $20.7 million in 2026.
• Business Quant data shows ELVN's Research & Development at $20.7 million in Q1 2026, $21.2 million in Q4 2025, and $18.2 million in Q3 2025.